NCT03760263View on ClinicalTrials.gov

Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus

PHASE4CompletedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions

Transplant;Failure,Kidney

Interventions

DRUG

Tacrolimus

Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.

Trial Locations (1)

23507

Sentara Norfolk General Hospital, Norfolk

Sponsors

Collaborators (1)

Veloxis Pharmaceuticals

All Listed Sponsors

collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Sentara Norfolk General Hospital

OTHER

NCT03760263 - Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus | Biotech Hunter | Biotech Hunter